Implications of Pharmacogenetic Testing for Clopidogrel Therapy in a Tertiary Healthcare Hospital in North India

Background Clopidogrel hyporesponsiveness with decreased antiplatelet activity is prevalent in percutaneous coronary intervention (PCI) patients due to reduced function polymorphism in the CYP2C19 enzyme gene which results in poor conversion of this prodrug to an active metabolite. However, pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Amarapalli, Jayachandra, Sharma, Prabhat, Datta, Rajat, Sharma, Anuka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439363/
https://www.ncbi.nlm.nih.gov/pubmed/37602077
http://dx.doi.org/10.7759/cureus.42169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439363/
https://www.ncbi.nlm.nih.gov/pubmed/37602077
http://dx.doi.org/10.7759/cureus.42169

Ejemplares similares